National Disability Rating: Neoplastic Disease Assessment | Althox
National Disability Rating: Neoplastic Disease Assessment in Colombia (Decree 917 of 1999)
The assessment of disability in Colombia is governed by a robust legal framework, with Decree 917 of 1999 serving as a cornerstone for determining the percentage of impairment due to various health conditions. This decree, particularly in its Chapter VIII, provides detailed guidelines for evaluating neoplastic diseases, commonly known as cancers. Understanding these criteria is crucial for both medical professionals and individuals navigating the disability rating process.
This second part of our comprehensive analysis delves into the specifics of neoplastic disease assessment, offering an in-depth look at the considerations, evaluation methods, and specific characteristics that lead to a 40% impairment rating. The intent is to clarify how a complex medical condition like cancer is translated into a quantifiable disability percentage within the Colombian legal and medical context.
The evolution of medical science has significantly changed our understanding of neoplastic diseases. What was once almost universally equated with severe disability is now viewed with a more nuanced perspective, recognizing the potential for remission, effective treatment, and varying degrees of impact on an individual's functional capacity. This chapter of Decree 917 reflects this modern understanding, emphasizing a holistic evaluation that goes beyond the mere diagnosis of cancer.
Table of Contents
- General Considerations for Neoplastic Disease Assessment
- Detailed Considerations for Assessment
- Evaluation of Neoplastic Disease
- Characteristics of Cancers with 40% Deficiency
- Head and Neck Cancers
- Skin Sarcoma
- Soft Tissue Sarcoma
- Malignant Melanoma
- Lymphoma (Hodgkin's and non-Hodgkin's)
- Lymph Nodes
- Salivary Glands
- Thyroid
- Breast Cancer
- Bone System
- Upper and Lower Jaw, Orbit or Temporal Fossa
- Brain Tumor and Spinal Cord
- Lungs
- Pleura and Mediastinum
- Abdomen
- Esophagus
- Stomach
- Small Intestine
- Large Intestine
- Liver and Gallbladder
- Pancreas
- Kidneys, Adrenal or Ureters
- Bladder
- Prostate
- Testicle
- Uterus
- Ovary
- Fallopian Tube
- Leukemia
- Myeloma
- Acquired Immunodeficiency Syndrome (HIV/AIDS)
Digital illustration symbolizing the intricate process of evaluating neoplastic diseases under Colombian disability law.
General Considerations for Neoplastic Disease Assessment
The Colombian Decree 917 of 1999, specifically Chapter VIII, outlines the framework for assessing neoplastic diseases within the national disability rating system. It acknowledges that simply having a neoplasm or a history of one does not automatically equate to disability. Instead, a comprehensive evaluation is required to determine the debilitating impact of cancer on a patient's life.
The assessment process is designed to be thorough, taking into account various factors that influence the severity and prognosis of the disease. This multi-faceted approach ensures that the disability rating accurately reflects the individual's functional limitations and the overall burden of their condition.
8. NEOPLASTIC DISEASE
8.1 General
It should be noted that with new knowledge of these pathologies, the bearer of a neoplasia or a history of having it is not synonymous with disability. It must meet the requirements and conditions specified in this chapter to consider the patient's debilitating cancer. Determining the percentage of impairment resulting from malignant tumors based on:
- The location and size of tumor,
- The tumor invasion to neighboring organs,
- The extension to regional lymph nodes
- The Distant metastases
- The histology
- The degree of response to treatment (surgery, radiation, hormones, chemotherapy), and
- The magnitude of the consequences post-treatment.
This initial section highlights the critical shift from a blanket diagnosis to a detailed analysis of the disease's characteristics and its response to medical interventions. Factors such as tumor location, size, invasiveness, and metastatic spread are paramount. Moreover, the effectiveness of treatments like surgery, radiation, hormonal therapy, and chemotherapy, along with their resulting sequelae, are integral to the final disability determination.
Detailed Considerations for Assessment
The process of assessing neoplastic disease for disability purposes requires meticulous documentation and a thorough understanding of the disease's progression and treatment outcomes. Several key considerations guide evaluators in reaching an accurate and fair rating.
8.2 CONSIDERATIONS FOR ASSESSMENT
In malignant diagnosis should be established based on the signs and symptoms, reports of examinations and diagnostic aid pathology, among others. You should also consider:
a) The site of the primary lesion, recurrent or metastatic disease should be documented in all cases of malignant neoplasm. If surgery was performed should include a reliable copy of the protocol and surgical pathology report of the part or biopsy. If you can not obtain these documents, the hospitalization epicrisis the physician's report should include details of the surgical findings and results of examinations (gross and microscopic) made by the pathologist.
b) If there is disease progression by the treating physician, it must send an updated medical report including recent surveys specifically aimed at determining local recurrence, lymph node, metastasis to other organs and probable sequelae after treatment.
c) For purposes of qualifying or opinion, the concept of lymph node metastases distance refers to the node tumor invasion beyond the limits of radical en bloc resection.
d) local or regional recurrence after radical surgery or anatomo-pathological evidence of incomplete excision in radical surgery is considered equal to the injury "inoperable" and for purposes of the rating should be evaluated as such, except for breast cancer.
e) The local or regional recurrence after complete removal of a tumor located, should not be considered equal to the recurrence after radical surgery.
f) The histological diagnosis of cancer is and should be documented with the original submission of the report issued by a pathologist, in case of no agreement between what was reported and the clinical, laboratory examinations, should be resorted to interconsultation pathologist requesting another shipment of plates and blocks shows that originated the diagnosis. The cytology report of either liquid or bodies shall be considered when dealing with patients with disseminated disease, such as neoplastic cells in ascites, pleural, etc. It is essential that the assessor also has the spread of cancer studies, such as imaging (RX, ECO, TAC, etc..) And radionuclides in asymptomatic patients. Moreover, in a patient with gastric cancer and a palpable mass at the level of right upper quadrant enough just endoscopy and histological report for finding a deficiency of 40%. In lymphomas, histological type and the compromised sites are not necessarily indicative of total disability. When the tumor involvement extends beyond the regional lymph nodes, the damage will generally be considered as severe.
The emphasis on precise documentation, including surgical protocols, pathology reports, and updated medical records, underscores the scientific rigor required for these assessments. The distinction between different types of recurrence and metastatic spread is crucial, as these factors significantly influence the disability percentage. The decree also specifies the importance of histological diagnosis and the use of advanced imaging techniques to confirm the extent of the disease, even in asymptomatic patients. This ensures a comprehensive understanding of the cancer's impact.
Evaluation of Neoplastic Disease
Evaluating neoplastic disease involves a multifaceted approach that considers the tumor itself, the consequences of its treatment, or both. The guidelines provided aim to standardize this process, ensuring consistency and fairness in disability ratings.
8.3 Evaluation of neoplastic disease
These guidelines provide criteria to evaluate and quantify the deficiency caused by the presence of a neoplastic disease, the consequences that may arise from the treatment, or both.
a) In cases where a tumor and / or its metastases are hormone dependent, isótoposensibles, or both, or there is disappearance of the primary tumor or its metastases in a follow-up period of at least 3 years, the deficiency is determined in accordance with assessment of the damage to the corresponding organ system. Example: In a seminoma operated and treated, the deficiency is defined based on the presence or absence of sexual problems, must be cataloged in accordance with the provisions of Chapter VI.
b) When the malignancy is localized or regional lymph nodes involves only apparently were completely removed with or without radiotherapy, and is not expected metastasis or recurrence in the short term, the deficiency should be considered as described in the paragraph a), evaluating the resulting damage to the organ system involved by the tumor. The exceptions to these cases are outlined in section 8.4.
c) Effects of surgical therapy, significant postoperative sequelae must be evaluated according to the state of the organ system affected. If you made an extended gastrectomy, a colostomy or nephrectomy, gastrectomy deficiency depend on its own or its complications, such as dumping syndrome, malnutrition, etc., The colostomy should be considered with the percentage of disability resulting from an ostomy and nephrectomy the percentage given in the chapter for this disease.
d) Effects of chemotherapy and radiation therapy: The impact caused by these types of procedures should be considered the treatment outcome and adverse response to therapy. These may vary greatly, so that each case must be studied individually. It is important to get the attending physician complete the treatment plan, including medication, dose, frequency of administration and duration. Obtain a description of complications or adverse responses to therapy, such as nausea, vomiting, diarrhea, weakness, skin disorders or reactive mental disorders and the severity of these effects in anticancer chemotherapy may change during the period of administration drug. Evaluation of patients with regard to the impact of therapy with drugs or radiation, should be based on observation during a period sufficient to allow a proper determination of the deficiency on this ground.
e) There may be a patient with a history of being a carrier of a cancer, which at the time to evaluate it is only periodic checks and no evidence of active tumor disease. In this case, the failure rate is given by the aftermath of treatment, if any, such as total laryngectomy, nephrectomy, amputation, total gastrectomy, etc., And not by the statistical forecast.
f) When a cancer patient refused any treatment, you should inform the patient of the risk of your decision, you should rate the current state and to conduct periodic reviews in accordance with the clinical course of cancer to alter the percentage of deficiency, when be the case.
g) In the case of patients considered curative treatment, it was ruled under "Monitoring and Treatment" and will be periodic reviews in accordance with the clinical course of cancer to alter the percentage of impairment, when appropriate.
This section emphasizes the dynamic nature of cancer assessment. It differentiates between cases where the tumor is responsive to treatment (hormone-dependent, radiosensitive) and those with localized malignancies that have been completely removed. The long-term effects of surgical interventions, such as gastrectomy or colostomy, are also carefully considered, focusing on the resulting functional impairments rather than the cancer itself once it's deemed under control.
Furthermore, the decree addresses the significant impact of chemotherapy and radiation therapy, acknowledging their potential for severe side effects. Individualized assessment of these treatment-related complications is paramount. It also provides guidance for patients in remission, those who refuse treatment, and those undergoing active monitoring, ensuring that the disability rating remains current and reflective of their evolving health status.
Medical records and diagnostic tools are essential for a precise disability evaluation.
Characteristics of Cancers with 40% Deficiency
Certain types of cancers, due to their inherent aggressiveness, location, or resistance to treatment, are specifically identified as leading to a 40% overall deficiency. This section details these specific scenarios, providing a clear benchmark for evaluators.
8.4 CHARACTERISTICS OF CANCERS WITH DEFICIENCY OF 40%
Neoplasms by histologic type, location and extent of the injury are inoperable or are out of control for other therapies, have an overall deficit of 40.0%.
8.4.1 Head and Neck
The head and neck tumors other than salivary glands, thyroid, upper and lower jaw, orbit and temporal fossa, corresponding to this classification when:
- a) Inoperable
- b) Not controlled by the therapy given.
- c) Recurrences after surgery, radiation, or both.
- d) They have distant metastases.
- e) Squamous cell carcinoma of the pyriform sinus or posterior third of tongue (not included carcinoma of the tonsil).
8.4.2 Skin Sarcoma
a) Angiosarcoma with regional lymph node metastases.
b) systemic fungal infections with liver involvement or visceral.
8.4.3 Soft Tissue Sarcoma
a) Inoperable.
b) Distant metastasis.
c) recurrent cancer after radical surgery followed by radiation therapy or not.
8.4.4. Malignant Melanoma
a) recurrence after radical surgery.
b) Metastasis to the adjacent skin or other organs.
8.4.5. Lymphoma
Hodgkin's and non-Hodgkin's lymphoma with progressive disease despite treatment.
8.4.6 Lymph Nodes
a) metastatic adenopathy of unknown primary.
b) Squamous cell carcinoma of lymph node in the neck that does not respond to treatment.
8.4.7. Salivary glands
a) carcinoma or sarcoma with metastases beyond the regional lymph nodes.
b) recurrence after radical treatment.
8.4.8. Thyroid
a) Carcinoma with metastases beyond the regional lymph nodes, not controlled by treatment made.
b) local recurrence not controlled by prescribed therapy.
8.4.9. Mama
a) Cancer inoperable.
b) Cancer inflammatory.
c) local and regional recurrence uncontrolled.
d) Distant metastasis or bilateral breast cancer.
e) Sarcoma with metastases anywhere.
04/08/1910. Bone System (excluding the mandible)
a) Primary malignant tumors with evidence of metastasis or uncontrolled therapy prescribed.
b) bone metastases of unknown origin after an adequate search.
08/04/1911. Upper and lower jaw, orbit or temporal fossa
a) Sarcoma of any type with metastases.
b) Carcinoma of the cavity with extension into the orbit or ethmoid or sphenoid, with or without metastasis regional.
c) orbital tumors with intracranial extension.
d) tumor of the temporal fossa with perforation of the skull or meningeal complications.
e) Adantinoma with intracranial and orbital infiltration.
f) Rathke sac tumors with infiltration of the base of the skull or metastases.
08/04/1912. Brain Tumor and Spinal Cord
a) malignant gliomas, grade III-IV astrocytomas, glioblastoma multiforme, medulloblastoma, ependymoblastoma and primary sarcoma;
b) O, grade I-II astrocytomas, meningioma, pituitary tumors, oligodendroglioma, ependymoma and benign tumors. These should be evaluated by the collateral damage that occur as: epilepsy, organic brain damage or neurological deficits.
08/04/1913. Lungs
a) ineradicable.
b) Metastasis.
c) relapse after treatment.
d) incompletely excised tumor.
e) small cell carcinoma.
08/04/1914. Pleura and Mediastinum
a) Malignant mesothelioma of the pleura.
b) Malignant tumor with metastasis to the pleura.
c) primary malignant tumor of the mediastinum not controlled by prescribed therapy.
04/08/1915. Abdomen
a) peritoneal carcinomatosis.
b) retroperitoneal malignant tumor not controlled by prescribed therapy.
c) Ascites with demonstrated malignant cells.
04/08/1916. Esophagus
a) Carcinoma or sarcoma of the upper two thirds of the esophagus.
b) Carcinoma or sarcoma of the distal esophagus with regional node metastases or infiltration of neighboring structures.
08/04/1917. Stomach
a) Carcinoma of stomach with metastasis to regional lymph nodes or tumor invasion to adjacent organs.
b) Kaposi not controlled by adequate therapy.
c) Inoperable.
d) recurrence or metastasis after radical surgery.
e) lymphomas according to the progression of disease.
08/04/1918. Small Intestine
a) carcinoma, sarcoma, or carcinoid tumor with metastases beyond the regional lymph nodes.
b) Recurrence after previous excision.
c) Kaposi not controlled by the described therapy.
08/04/1919. Intestine
a) unresectable
b) metastases beyond the regional lymph nodes.
c) recurrence or metastasis after excision.
04/08/1920. Liver and Gallbladder
a) primary or metastatic malignant tumors.
b) invasive carcinoma of the gallbladder.
c) unresectable bile duct carcinoma or metastases.
04/08/1921. Pancreas
a) Carcinoma, except cel Cancer. islet.
b) Carcinoma of the islet cell in unresectable or physiologically active.
04/08/1922. Kidneys, adrenal or Ureters Pigeon
a) ineradicable.
b) With metastases
08/04/1923. Bladder
a) Infiltration beyond the bladder wall.
b) ineradicable.
c) Metastasis
d) Evaluate renal impairment after total cystectomy according to the criteria applied in that chapter.
08/04/1924. Prostate
Carcinoma not controlled by prescribed therapy and well run.
08/04/1925. Testicle
a) Choriocarcinoma, not controlled by adequate therapy.
b) Other primary malignant tumors with progressive disease not controlled with therapy indicated.
08/04/1926. Uterus
Carcinoma - Adenocarcinoma and Sarcoma.
a) Inoperable and not controlled with proper treatment.
b) recurrence after radical hysterectomy or radiotherapy.
c) total pelvic exenteration.
04/08/1927. Ovary
a) Ascites with demonstrated malignant cells.
b) Tumor unresectable or partially removed.
c) unresectable metastases of the abdominal cavity.
d) Distant metastasis.
04/08/1928. Fallopian tube
Carcinoma or unresectable or metastatic sarcoma.
04/08/1929. Leukemia
a) acute lymphocytic leukemia or nonlymphocytic completely unresponsive, refractory to initial treatment.
b) acute leukemia relapses during the maintenance period of therapy or treatment while outside.
c) chronic myeloid leukemia unresponsive to treatment or is in the stage of transformation or blast crisis.
d) chronic lymphocytic leukemia in advanced stage with symptoms of anemia and thrombocytopenia or unresponsive to treatment.
08/04/1930. Myeloma
Confirmed by electrophoresis of proteins in urine or serum and bone marrow examination appropriate. With:
- a) radiological evidence of bone disease with intractable osteoalgias or pathologic fractures;
- b) Or, evidence of kidney damage;
- c) Or, Hypercalcemia with persistent serum levels of 11 mg/100 ml for at least 1 month despite prescribed therapy;
- d) O, plasma cells, 100 or more cells per ml in peripheral blood.
Head and Neck Cancers
Tumors in the head and neck region, excluding those of the salivary glands, thyroid, jaws, orbit, and temporal fossa, are assigned a 40% deficiency if they are inoperable, uncontrolled by therapy, recur after treatment, or have distant metastases. Specific mention is made of squamous cell carcinoma of the pyriform sinus or posterior third of the tongue, highlighting the severe impact of these particular presentations.
Skin Sarcoma
Angiosarcoma with regional lymph node metastases and systemic fungal infections with liver or visceral involvement are classified under this category, indicating the aggressive nature and systemic impact required for a 40% rating.
Soft Tissue Sarcoma
Similar to other aggressive cancers, soft tissue sarcomas are rated at 40% if they are inoperable, have distant metastases, or recur after radical surgery, even with radiation therapy.
Malignant Melanoma
Recurrence after radical surgery or metastases to adjacent skin or other organs are the key criteria for a 40% deficiency in cases of malignant melanoma, reflecting its potential for aggressive spread.
Lymphoma (Hodgkin's and non-Hodgkin's)
Lymphomas, both Hodgkin's and non-Hodgkin's types, qualify for a 40% deficiency if they show progressive disease despite ongoing treatment, indicating a poor prognosis and significant functional impairment.
Lymph Nodes
Metastatic adenopathy of unknown primary origin or squamous cell carcinoma of a neck lymph node that is unresponsive to treatment are also categorized here, emphasizing the severity of uncontrolled lymphatic involvement.
Salivary Glands
Carcinomas or sarcomas of the salivary glands with metastases beyond regional lymph nodes or recurrence after radical treatment are considered for a 40% deficiency.
Thyroid
Thyroid carcinomas with metastases beyond regional lymph nodes not controlled by treatment, or local recurrence not controlled by prescribed therapy, meet the 40% criteria.
Breast Cancer
Breast cancer is rated at 40% if it is inoperable, inflammatory, exhibits uncontrolled local and regional recurrence, has distant metastases, or is bilateral. Sarcomas of the breast with metastases anywhere also fall into this category.
Bone System
Primary malignant bone tumors with metastasis or uncontrolled by therapy, and bone metastases of unknown origin after a thorough search, are assigned a 40% deficiency.
Upper and Lower Jaw, Orbit or Temporal Fossa
This category includes sarcomas with metastases, carcinomas extending into the orbit or ethmoid/sphenoid, orbital tumors with intracranial extension, temporal fossa tumors with skull perforation or meningeal complications, and specific rare tumors like adantinoma and Rathke sac tumors with infiltration or metastases.
Brain Tumor and Spinal Cord
Malignant gliomas (grade III-IV astrocytomas, glioblastoma multiforme, medulloblastoma, ependymoblastoma, primary sarcoma) are rated at 40%. Benign tumors in these areas (grade I-II astrocytomas, meningioma, pituitary tumors, oligodendroglioma, ependymoma) are evaluated based on collateral damage such as epilepsy, organic brain damage, or neurological deficits.
Lungs
Lung cancers are rated at 40% if they are ineradicable, metastatic, relapse after treatment, are incompletely excised, or are small cell carcinomas, reflecting their often aggressive nature and poor prognosis.
Pleura and Mediastinum
Malignant mesothelioma of the pleura, malignant tumors with pleural metastasis, or primary mediastinal tumors not controlled by therapy are assigned a 40% deficiency.
Abdomen
Conditions like peritoneal carcinomatosis, retroperitoneal malignant tumors not controlled by therapy, and ascites with demonstrated malignant cells are rated at 40% due to their widespread and often intractable nature.
Esophagus
Carcinomas or sarcomas of the upper two-thirds of the esophagus, or those of the distal esophagus with regional node metastases or infiltration of neighboring structures, qualify for a 40% deficiency.
Stomach
Gastric carcinoma with regional lymph node metastasis or invasion to adjacent organs, uncontrolled Kaposi's sarcoma, inoperable cases, recurrence or metastasis after radical surgery, and lymphomas with disease progression are all rated at 40%.
Small Intestine
Carcinomas, sarcomas, or carcinoid tumors with metastases beyond regional lymph nodes, recurrence after excision, or Kaposi's sarcoma not controlled by therapy are assigned a 40% deficiency.
Large Intestine
Unresectable tumors, metastases beyond regional lymph nodes, or recurrence/metastasis after excision lead to a 40% deficiency rating for large intestine cancers.
Liver and Gallbladder
Primary or metastatic malignant tumors of the liver, invasive carcinoma of the gallbladder, or unresectable bile duct carcinoma/metastases are rated at 40%.
Pancreas
Pancreatic carcinoma (except islet cell cancer) and unresectable or physiologically active islet cell carcinoma are assigned a 40% deficiency, reflecting the typically aggressive nature of these cancers.
Kidneys, Adrenal or Ureters
Ineradicable tumors or those with metastases in these organs lead to a 40% deficiency.
Bladder
Bladder cancers with infiltration beyond the bladder wall, ineradicable tumors, or metastases are rated at 40%. Renal impairment after total cystectomy is evaluated separately.
Prostate
Prostate carcinoma not controlled by prescribed and well-executed therapy is assigned a 40% deficiency.
Testicle
Uncontrolled choriocarcinoma or other primary malignant testicular tumors with progressive disease not controlled by indicated therapy lead to a 40% deficiency.
Uterus
Uterine carcinomas, adenocarcinomas, and sarcomas are rated at 40% if they are inoperable and uncontrolled, recur after radical hysterectomy or radiotherapy, or require total pelvic exenteration.
Ovary
Ovarian cancer with ascites demonstrating malignant cells, unresectable or partially removed tumors, unresectable metastases of the abdominal cavity, or distant metastasis are assigned a 40% deficiency.
Fallopian Tube
Carcinoma or unresectable or metastatic sarcoma of the fallopian tube also falls under the 40% deficiency category.
Leukemia
Acute lymphocytic or nonlymphocytic leukemia that is completely unresponsive or refractory to initial treatment, acute leukemia relapsing during maintenance therapy or off-treatment, chronic myeloid leukemia unresponsive to treatment or in blast crisis, and advanced chronic lymphocytic leukemia with specific symptoms are rated at 40%.
Myeloma
Myeloma confirmed by specific laboratory findings, accompanied by radiological evidence of bone disease, kidney damage, persistent hypercalcemia, or a high count of plasma cells in peripheral blood, is assigned a 40% deficiency.
The path through cancer treatment is often complex and requires careful consideration for disability ratings.
Acquired Immunodeficiency Syndrome (HIV/AIDS)
Beyond neoplastic diseases, Decree 917 of 1999 also provides criteria for evaluating patients infected with HIV or those with AIDS. The assessment focuses on the restriction, absence, or functional deficiencies caused by the condition, integrating epidemiological, laboratory, and clinical criteria.
8.5 ACQUIRED IMMUNODEFICIENCY SYNDROME
The criteria for evaluation of patients infected with HIV or AIDS patient are given in terms of the restriction, absence or functional deficiencies. Should consider three criteria to reach a diagnosis of HIV and AIDS, as follows:
1. Epidemiological approach: The epidemiological approach is the starting point of diagnosis and includes various forms of transmission and risk history and positive contacts.
2. Laboratory criteria: The laboratory approach based on the demonstration of the virus, its products or antibodies produced against different viral proteins. Diagnostic methods are categorized into:
- a) Detection of antibodies presumptive tests (ELISA), additional evidence (Western-Blood, immunofluorescence, rapid test or immuno-blot), among others.
- b) Detection of the virus or its products: Virus isolation, antigen P24 chain reaction (PCR), among others.
- c) Additional laboratory tests, immune profile, blood count and erythrocyte sedimentation rate, lymphocyte population, CD4/CD8 ratio, delayed hypersensitivity immunological tests, among others.
3. Clinical criteria: The clinical criteria is given by the detection of signs and symptoms in relation to AIDS. Always keep in mind that the incubation period can last several years and that not all clinical manifestations will occur in all patients, since the same change can have different characteristics in people. HIV may directly affect the agency to significantly reduce the level of immune defenses and may trigger a series of diseases secondary to this. For the evaluation of impairment classification is used HIV / AIDS CDC/Atlanta/93, which includes consideration of a parameter for clinical evaluation and other laboratory, based on the T4 cell count or CD4 cells. The rating applies to those who alrea..."
The evaluation of HIV/AIDS patients for disability purposes is a complex process that relies on a combination of epidemiological, laboratory, and clinical data. This holistic approach ensures that the assessment considers not only the presence of the virus but also its impact on the individual's immune system and overall health. The incubation period, variable clinical manifestations, and the direct effect of HIV on immune defenses are all critical factors in determining the level of impairment.
The use of the CDC/Atlanta/93 classification for HIV/AIDS impairment evaluation, which incorporates clinical parameters and T4 or CD4 cell counts, highlights the scientific basis of these assessments. This structured approach allows for a consistent and evidence-based determination of disability, reflecting the current medical understanding of the disease.
In conclusion, Decree 917 of 1999 provides a detailed and scientifically informed methodology for assessing disability arising from neoplastic diseases and HIV/AIDS in Colombia. By considering a wide range of factors, from tumor characteristics and treatment outcomes to the specific clinical and laboratory markers of HIV progression, the decree aims to ensure fair and accurate disability ratings that reflect the true functional limitations faced by individuals with these complex conditions.
Fuente: Contenido híbrido asistido por IAs y supervisión editorial humana.
Comentarios